Navigation Links
Sysmex America Begins Distribution of CellaVision® DM1200
Date:7/20/2010

MUNDELEIN, Ill., July 20 /PRNewswire/ -- Sysmex, a global leader in medical diagnostic testing equipment and information systems technology, today announced the addition of the CellaVision® DM1200 cell image analysis analyzer to the Sysmex hematology product offering.  The DM1200 enables Sysmex America to meet the growing demand for automated cell image analysis, which improves both the quality of results and the productivity of laboratories performing mid-volume testing.    

The CellaVision® DM1200 opens up new ways of handling manual differentials traditionally performed on a microscope by automatically performing a preliminary differential count on peripheral blood. The analyzer pre-classifies the white blood cells, pre-characterizes parts of the red morphology and provides functionality for platelet estimation. By automating the manual differential, laboratories can experience enhanced turnaround times without sacrificing quality.  Its high degree of automation allows for an escalating workload without increasing labor.

"The CellaVision DM1200, which locates, identifies, and pre-classifies blood cells by means of automatic microscopy and advanced image processing, greatly enhances Sysmex America's hematology product offering.  We trust this addition to our hematology portfolio will serve our customers well as they continue to navigate through a challenging health care environment," said John Kershaw, President & CEO, Sysmex America, Inc.    

Sysmex America and CellaVision first initiated their working relationship in 2004.  Today, Sysmex Corporation and CellaVision have an extended and broadened working relationship via the completion of a recent global distribution agreement.  The agreement gives Sysmex a non-exclusive right to sell CellaVision's products in hematology laboratories worldwide.  As of April 1, 2010, the non-exclusive agreement comprises all international markets but Canada.  

About CellaVision

CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.  The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.  CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.

About Sysmex America, Inc.

Sysmex America, Inc., the U.S. headquarters of Sysmex Corporation (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation and information systems.  Serving customers for over 40 years, Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide.  For more information about Sysmex, please visit www.sysmex.com/usa.


'/>"/>
SOURCE Sysmex America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OhioHealth Installs Newest Version of Sysmexs Hematology Middleware, Sysmex WAM(TM) 4.0
2. Sysmex America Adds Industry Veteran to Company Leadership
3. Sysmex America Honored Second Consecutive Year as a Company That Cares
4. Sysmex America Announces Executive Leadership Changes
5. Sysmex America Announces Amerinet Urinalysis Contract
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
8. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
9. Aspirin Named 8th World Wonder by Majority of Americans
10. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
11. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... their offering. ... The global chromatography market to grow at a ... Market 2016-2020, has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
(Date:12/8/2016)... , December 8, 2016 ... "Sugar-Based Excipients Market by Product (Actual Sugars, Sugar ... (Filler & Diluent, Tonicity Agents), Formulation (Oral, Topical, ... MarketsandMarkets, the market has witnessed healthy growth during ... at a CAGR of 4.3% between 2016 and ...
(Date:12/8/2016)... , Dec. 8, 2016  Agenovir Corporation, a ... novel antiviral therapeutics, today announced that it appointed ... officer and a member of the board of ... executive with a deep background in both founding ... founder of Agenovir, co-president of Chan Zuckerberg  Biohub ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had joined the Pharmaceutical ... a non-profit organization to unite pharmaceutical and healthcare companies that share a vision ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
Breaking Medicine News(10 mins):